Ludwig Michael, Utsch Boris, Balluch Bernd, Fründ Stefan, Kuwertz-Bröking Eberhard, Bökenkamp Arend
Department of Clinical Biochemistry, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany.
Pediatr Nephrol. 2006 Sep;21(9):1241-50. doi: 10.1007/s00467-006-0172-9. Epub 2006 Jun 29.
Hypercalciuria is regarded as a characteristic symptom of Dent disease, an X-linked recessive tubulopathy characterized by low molecular weight (LMW) proteinuria, nephrocalcinosis/nephrolithiasis, and progressive renal failure due to mutations in the CLCN5 gene. As the presence of hypercalciuria may affect the decision to consider a CLCN5 mutation in the differential diagnosis, the phenotypic spectrum and the relative frequency of hypercalciuria in patients with CLCN5 mutations was determined. We assessed renal calcium excretion in 34 male patients with proven CLCN5 mutations, who had been referred because of LMW proteinuria and at least one additional symptom of Dent disease. Hypercalciuria was defined as renal calcium excretion exceeding 0.1 mmol/kg per day. Data obtained were compared with all series of CLCN5-positive patients identified by a systematic literature survey. In 7 of our 19 families, at least 1 affected male had normal calcium excretion. Hypercalciuria was observed in 22 of 31 patients tested (71%) compared to 85 of 90 (94.4%) in series from Europe and North America and 74.4% from Japan. LMW proteinuria was present in all CLCN5-positive patients; 25% of the patients in European and North American series, 45% of the Japanese, and 41% in the present series had only two of the four principal symptoms of Dent disease. Therefore, a CLCN5 mutation should be considered irrespective of the presence of hypercalciuria in a patient with LMW proteinuria and one additional symptom of Dent disease.
高钙尿症被视为丹特病的一个特征性症状,丹特病是一种X连锁隐性肾小管病,其特征为低分子量(LMW)蛋白尿、肾钙质沉着症/肾结石,以及由于CLCN5基因突变导致的进行性肾衰竭。由于高钙尿症的存在可能会影响在鉴别诊断中考虑CLCN5突变的决策,因此确定了CLCN5突变患者中高钙尿症的表型谱和相对频率。我们评估了34名经证实有CLCN5突变的男性患者的肾脏钙排泄情况,这些患者因LMW蛋白尿和至少一种丹特病的其他症状前来就诊。高钙尿症定义为肾脏钙排泄量超过每天0.1 mmol/kg。将获得的数据与通过系统文献调查确定的所有CLCN5阳性患者系列进行比较。在我们的19个家族中,有7个家族中至少有1名受影响男性的钙排泄正常。在31名接受检测的患者中,有22名(71%)出现高钙尿症,相比之下,欧洲和北美的系列研究中90名患者中有85名(94.4%)出现高钙尿症,日本的系列研究中有74.4%的患者出现高钙尿症。所有CLCN5阳性患者均存在LMW蛋白尿;欧洲和北美系列研究中有25%的患者、日本有45%的患者以及本系列研究中有41%的患者仅出现丹特病四个主要症状中的两个。因此,对于有LMW蛋白尿且伴有丹特病其他一种症状的患者,无论是否存在高钙尿症,都应考虑CLCN5突变。